Pyxis Oncology (PYXS)
NASDAQ:PYXS
Want to see PYXS full AI Analyst Report?
PYXS Stock Chart & Stats
$1.66
-$0.10(-5.75%)
At close: 4:00 PM EST
$1.66
-$0.10(-5.75%)
Day’s Range― - ―
52-Week Range$0.97 - $5.55
Previous CloseN/A
Volume258.73K
Average Volume (3M)757.02K
Market Cap
$128.61M
Enterprise Value$131.39M
Total Cash (Recent Filing)$42.49M
Total Debt (Recent Filing)$18.26M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 19, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding63,355,480
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.34
Price to Sales (P/S)5.16
P/FCF Ratio-1.13
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue9.48
Enterprise Value/Gross Profit9.50
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$6.50Price Target Upside291.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.25
Revenue Forecast (FY)$43.75K
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment For Pivotal MICVO TrialSecuring FDA alignment on pivotal trial design materially reduces regulatory uncertainty and clarifies the evidentiary bar the company must meet. This durable de-risking enables more efficient trial planning, constructive regulator dialogue, and stronger positioning for future approvals or partnerships over the next 2–6 months.
Completed Phase 1 Expansion Enrollment; Data Readouts PlannedCompleting target enrollment and scheduling mid/late-2026 readouts provides an imminent, structural catalyst: first clinical efficacy/safety signals will inform dose selection and pivotal design. Results can meaningfully shift development trajectory, partnership prospects, and resource allocation beyond short-term market noise.
Cash Runway Extended Into Q4 2026An extended cash runway through Q4 2026 gives management a multi-quarter window to deliver planned clinical readouts and pursue regulatory engagement without immediate refinancing. This improves operational optionality and executionability for pivotal planning, though it does not eliminate medium-term funding needs.
Bears Say
Heavy And Persistent Cash BurnSustained negative operating and free cash flow near -$67M TTM imposes continuous financing pressure. Over 2–6 months this burn rate will necessitate capital markets activity or partnerships to fund trials, risking dilution or changed terms that could impair long-term shareholder value and program continuity.
Shrinking Equity Base And AssetsA marked decline in shareholders' equity and total assets reduces the company's financial cushion against trial setbacks or unexpected expenses. With a smaller equity base, Pyxis has diminished balance sheet flexibility and negotiating leverage for partnerships or financings over the medium term.
Limited, Declining And Non‑recurring RevenueRevenue is modest, fell about 14% in 2025, and appears driven by non-recurring milestones, so the company lacks sustainable commercial cash generation. Over the coming months this structural revenue weakness heightens dependence on external funding and magnifies development execution risk.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.97 and its highest was $5.55 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $128.61M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Aug 19, 2026 which is in 59 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on May 14, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.364 by -$0.006.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.35.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 63,355,480 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.364. Following the earnings report the stock price went down -15.649%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pyxis Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (291.57% Upside)
$6.50 (291.57% Upside)
Hedge Fund Trend
Decreased
By 161.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 4.8%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.23%
12-Months-Change
Fundamentals
Return on Equity
-135.60%
Trailing 12-Months
Asset Growth
-52.67%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$6.50
▲(291.57% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
2.81% Insiders
4.05% Mutual Funds
31.69% Other Institutional Investors
57.41% Public Companies and
Individual Investors